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Abstract 
American skullcap (Scutellaria lateriflora) is a popular herb in traditional medicine systems 
and western Materia medica for anxiety and related disorders.  It is reported to be one of the 
most widely used medicinal herbs, with anecdotal evidence for minimal side-effects and with 
no known toxicity.  This article summarises the results of a pilot survey conducted amongst 
herbal medicine practitioners on their use of S. lateriflora.  
 
An email survey was conducted amongst herbal medicine practitioners in the UK and Ireland.  
It aimed to gather information on the extent of, and indications for, current use of S. 
lateriflora, its perceived effectiveness and its safety.  Herbal medicine practitioners were 
selected from the membership list of the National Institute of Medical Herbalists (NIMH).  
All members with identifiable email addresses were contacted (n = 377) and responses were 
received from 62 (a 16% response rate).   
 
The results of the survey suggested that S. lateriflora is highly regarded among herbal 
medicine practitioners as an effective intervention for reducing anxiety and stress and is 
commonly prescribed for these conditions and related co-morbidities.  The results were not 
conclusive as the response rate was low and respondents were only those with email access. 
 
Keywords 







American or Virginian skullcap (Scutellaria lateriflora) (Figure 1) is a perennial herb 
belonging to the Lamiaceae (mint) family (also known as Labiatae), sub-family Lamioideae, 
and is one of 360 known Scutellaria species worldwide (Cole et al. 1991; Malikov & 
Yuldashev 2002), many of which are used medicinally (Joshee et al. 2002).  It grows on 
wetlands and is indigenous to North America and Canada where it is widely distributed - 
from Alaska to Florida and British Columbia to Quebec (the only places it is not found are 
the North-west Territories, Alberta and Yukon in Canada and Wyoming, Nevada and Utah in 
the US) (U.S.D.A. 2012). It is grown commercially worldwide, including in Australia and 





Figure 1 Scutellaria lateriflora (© C. Brock) 
 
 S. lateriflora is used extensively and has been highly valued in traditional western herbal and 
ethnobotanical medicines for anxiety, hysteria, phobias, panic attacks, tension, depression, 
sleep disorders and stress (Felter & Lloyd 1898; Joshee et al. 2002).  Known as a woman’s 
herb by Native Americans, the Cherokees used it as an emmenagogue, thus promoting 
menses and aiding expulsion of the placenta following childbirth.  Native American women 
also used it to ensure general menstrual health (Joshee et al. 2002) as well as for mastalgia 
and premenstrual tension (Greenfield & Davis 2004).  Some tribes still use it in ceremonies to 
induct girls into womanhood and for purification rituals (Joshee et al. 2002). 
 
The first European to record its use (in 1787) as a medicinal herb was German Physician 
Johann David Schöpff, who noted its use as a tonic, for fevers and as an abstergent 
(detergent) (Upton et al. 2009).  It was mentioned in the first American Materia medica in 
1785 but had been in longstanding use as a home remedy before then (Lloyd 1911).  Dr 
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Lawrence Van Derveer (1740-1815) studied S. lateriflora extensively and used it as a 
treatment for rabies (hydrophobia); it was then used for this purpose both professionally and 
as a home remedy.  In 1819 Dr Lyman Spalding wrote ‘A history of the introduction and use 
of Scutellaria lateriflora (scullcap), as a remedy for preventing and curing hydrophobia, 
occasioned by the bite … ’ (Lloyd 1911; New Jersey Historical Society 2001).  Medical 
doctor Joseph Bates wrote in 1855 in the Boston Medical Journal (Bates 1855) that because 
S. lateriflora was eventually scientifically proved to be utterly useless for this purpose it fell 
into disrepute and was consequently removed from pharmacopoeias.  He nevertheless 
described using S. lateriflora in his practice, claiming a fluid extract had great value in the 
treatment of nervousness, irritability and restlessness, particularly in children.  He also held it 
in high regard for hysteria and for relieving symptoms of inflammation in patients with 
arthritis or convalescing from fevers.  He prophesied that it would be found to be highly 
successful in treating many diseases in the future, particularly those for which opium was 
currently prescribed (Bates 1855).  In 1860 it was introduced into the official United States 
Pharmacopoeia as Extractum Scutellariae Fluidum (Millspaugh 1892; Upton et al. 2009) but 
was dropped in 1910.  It was in the US National Formulary in 1916 and removed in 1942 
when interest in natural remedies declined.  It is not included in the European 
Pharmacopoeia (Upton et al. 2009). 
 
Modern herbal medicine’s application of S. lateriflora appears to be based upon its traditional 
uses for anxiety states.  Greenfield and Davis (2004) for example, suggest it is used most 
commonly for insomnia, nervous disorders and digestive disturbances.  Bergner (2002) 
proposes its action is primarily as a trophorestorative on the central nervous system (CNS), 
allowing relaxation following nervous exhaustion (Bergner 2002).  It is also prescribed by 
western herbalists for epilepsy (British Herbal Medicine Association 1983), post-stroke 
paralysis, atherosclerosis, hyperlipidaemia, allergies, skin conditions and inflammation 
(Natural Medicines Comprehensive Database 2011). 
 
A small clinical study assessing acute effects of S. lateriflora indicated it has anxiolytic 
actions with minimal loss of cognition (Wolfson & Hoffmann 2003).  The authors assessed 
the anxiolytic properties of the herb in a double-blind, placebo-controlled crossover study of 
19 healthy volunteers.  Participants took either 2 placebo capsules, one capsule containing 
100 mg of organic freeze-dried S. lateriflora extract, two capsules of these, or one capsule of 
350 mg organic freeze-dried S. lateriflora.  Participants’ energy, cognition and anxiety were 
self-rated at various time points up to 2 hours following administration of test or placebo 
substances, when measurements tended to return to baseline.  The three herb tests all had 
notable effects in reducing subjective anxiety scores when compared to placebo, the most 
effective being the two 100 mg capsules.  There was only a very mild decline in cognition 
and energy with the herbs, with no adverse reactions or side-effects, suggesting that S. 
lateriflora could be a valuable anxiolytic - as many anxiolytics impair cognitive function and 
physical performance (Wolfson & Hoffmann 2003).  It is unclear whether the results were 
statistically significant as this was not determined. 
 
Furthermore, two studies found major skullcap flavonoids, including baicalin, baicalein and 
wogonin, extracted from S. baicalensis but also found in S. lateriflora, had affinities for the 
benzodiazepine binding site of gamma-aminobutyric acid A (GABAA) receptors, suggesting 
anxiolytic properties for these flavonoids (Liao et al. 1998; Hui et al. 2000). Ligands binding 
to the benzodiazepine site of the GABAA receptor decrease the likelihood of action potentials 
by excitatory neurotransmitters such as adrenalin and noradrenalin, implicated in anxiety and 
stress (Rabow et al. 1995; Paladini et al. 1999).  Another study found both hot water and 70% 
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ethanol extracts of whole aerial parts of S. lateriflora, as well as six major isolated flavonoids 
(baicalin, scutellarin, wogonin, lateriflorein, ikonnikoside I and dihydrobaicalin), bound to 
serotonin-7 (5-HT7) receptors, suggesting the potential of S. lateriflora for attenuation of 
negative mood states (Gafner et al. 2003). 
 
Modern pharmacology research has demonstrated anti-tumour, anti-inflammatory, anti-viral, 
antibacterial and hepatoprotective effects of individual compounds, particularly the 
flavonoids, found in the Scutellaria genus (Shang et al. 2010).  In common with all 
Scutellaria species studied S. lateriflora is rich in flavonoids, a group of phenolic compounds 
that are highly active physiologically, with a wide range of pharmacological actions (Malikov 
& Yuldashev 2002; Shang et al. 2010; Li et al. 2012).  Baicalin, baicalein and wogonin are 
considered to be major active flavonoids in S. lateriflora and have been researched 
extensively because of their presence also in S. baicalensis (Joshee et al. 2002; Li et al. 
2012). 
 
Since 1998 a large number of compounds have been isolated from S. lateriflora (Shang et al. 
2010), which could have far reaching implications for research into its actions and 
indications. Most recently (Li et al. 2012), using a sensitive method of HPLC with ultraviolet 
photodiode array and electrospray ionization tandem mass spectromic detection (HPLC-
DAD/ESI-MS), six more flavonoids were isolated from methanolic extracts of authenticated 
S. lateriflora aerial parts.  The flavonoids identified in this species for the first time are 
norwogonin-7-O-glucoronide, wogonin-7-O-glucoronide, 5,7-dihydroxy-6,8-dimethoxy 
flavone-7-O-glucoronide, dihidrooroxylin A-7-O-glucoronide, galangin-7-O-glucuronide, 
and 5,6,7-trihydroxy-flavanone-7-O-glucuronide (Li et al. 2012).  
 
More than one species within a genus may possess exactly the same or similar flavonoids.  
For example, in common with many other Scutellaria species, S. lateriflora and S. 
baicalensis have similar phytochemical constituents, although in different ratios and 
quantities, which may explain the differing traditional uses amongst Scutellaria species (Cole 
et al. 2008).  Using HPLC, Cole et al. (2008) quantitatively compared the content of 
flavonoids scutellarin, wogonin, baicalin and baicalein in aerial parts of S. lateriflora, S. 
baicalensis and S. racemosa grown in identical conditions.  S. lateriflora contained the 
highest amount of baicalein while S. baicalensis contained 800 times more scutellarin than 
the other two herbs.  Of the three herbs S. racemosa had the highest wogonin content.  
Baicalin content was similar for the three herbs (Cole et al. 2008), which differs from the 
findings of Makino et al. (2008) who found baicalin content in the leaves and stems of S. 
baicalensis was insignificant in comparison to S. lateriflora.  There was slightly more 
baicalin in S. baicalensis root than in S. lateriflora leaves (Makino et al. 2008).  Interestingly, 
of five skullcap species analysed (S. baicalensis, S. lateriflora, S. racemosa, S. tormentosa 
and S. wrightii), Islam et al. (2011) found a greater baicalin content in the roots of S. wrightii 
than in root, stem or leaf of the other species and 5-fold higher than in S. baicalensis root.  
The authors also demonstrated that S. wrightii and S. tormentosa, previously uncharacterised 
species, are good sources of the flavonoids scutellarin, baicalin, baicalein and wogonin.  As 
these flavonoids are also found in S. lateriflora there are implications that these species also 
have medicinal properties. It is possible that differences in flavonoid concentration between 
studies may have been due to differences in growing conditions. 
 
Commercial herbal products have been found to contain significant variations in 
phytochemical profile within a species.  Such variation may be according to geographic 
region, biodiversity, ecological variations, cultivation, seasonality, harvesting, and storage 
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time affecting stability; processing method, marc to menstruum ratio and alcohol 
concentration (Ciddi 2006; Gao et al. 2008).   
Notwithstanding these variations, another problem is whether or not the herb is the correct 
species.  Studies have shown wide variations in phytochemical profile of herb claimed to be 
S. lateriflora.  Zhang et al. (2009), for example, discovered a wide variation in individual and 
total phenolic content in 10 different commercial preparations of S. lateriflora (analysed by 
HPLC and compared with S. baicalensis and whole, freeze-dried extract).  Baicalin content, 
for example, varied from 0.48% to 10.10% (compared to 18.95% for whole extract).  Total 
phenolic content for these two preparations was 1.11% (extract – type not described) and 
20.55% (fine powder in a capsule) respectively (41% for whole extract) (Zhang et al. 2009). 
Another HPLC analysis (Gao et al. 2008), of seven commercial preparations (obtained from 
five companies), which compared baicalin, baicalein and wogonin content of S. lateriflora 
(four samples of S. baicalensis were also analysed), also found wide variations in individual 
and total content of these flavonoids.  One sample contained no baicalin, baicalein or 
wogonin.  Of all three flavonoids, µg/ml ranged from 180, 280 and 97.5 to 12,700, 629 and 
152 respectively (Gao et al. 2008).  One commercial S. lateriflora tincture tested by Gao et 
al. (2008), which had the highest flavonoid content (12.66 mg/ml), was extracted in 45% 
ethanol, whereas the others were extracted in 25% ethanol.  When the investigators later 
compared extraction in 25% and 45% ethanol from the same batch of S. lateriflora plant 
material they found that 45% ethanol yielded around five times more flavonoids than 25% 
ethanol (Gao et al. 2008).   
 
Quality control and correct identification may be of particular importance in the case of S. 
lateriflora because of the large number of Scutellaria species (Malikov & Yuldashev 2002) 
and frequent substitution or adulteration with other skullcaps or potentially harmful herbs 
such as germander (Teucrium) (Wolfson & Hoffmann 2003).  Respondents to the practitioner 
survey said they used a variety of suppliers, mainly for price, convenience or habit but it is 
important to ensure the herb has been authenticated. 
 
Anxiety, stress and related disorders are problems treated most frequently in the herbal 
medicine clinic (del Mundo et al. 2002).  As S. lateriflora is reported to be one of the most 
used herbs in western materia medica (Bergner 2002) it is likely that this is the herb of choice 
by western medical herbalists for these conditions.  The purpose of the survey was to provide 
further evidence for its popularity in relation to other herbs used for the same conditions, to 
gather anecdotal evidence of its effectiveness and to gain information about prescribing 
practices such as dosage and duration of treatment, why it is prescribed and any reported 
issues in using it.  The results may help to inform treatment protocols in clinical studies.  A 
brief version of the survey was reported previously (Brock et al. 2010) along with a more 
detailed scientific basis for the use of S. lateriflora. 
2. Materials and methods 
UK and Ireland herbal medicine practitioners with an email address identifiable from the 
register of the National Institute of Medical Herbalists (NIMH) were contacted.  NIMH 
members are qualified herbalists who have undergone several years’ rigorous scientific 
training, following which they take consultations with patients with a wide range of 
conditions, using the same diagnostic skills and examination techniques as orthodox doctors.  
This organisation was chosen as it is the largest organisation representing medical herbalists 
in the UK.  As a number of herbalists belong to more than one representing organisation there 
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was a risk of some receiving a survey questionnaire twice if more than one register was used.  
Each of the 377 practitioners selected received an electronic letter and survey questionnaire 
form. 
 
A mixed methods approach was used with mainly open questions in order to gather as much 
information as possible about practitioners’ experiences with, and beliefs about, S. lateriflora.  
Respondents were asked:  
 
• Whether they regularly prescribe S. lateriflora and, if not, reasons for not doing so;  
• what they thought were its main actions and indications;  
• what they prescribed it for and for how long;  
• the length of time in which they expect to see a response in patients and what responses 
they expected to see;  
• what patients reported from its use;  
• whether there have been any reported side-effects and what were perceived contra-
indications;  
• type of preparation used and reasons for choices;  
• dosage and strength;  
• whether used alone or in combination;  
• What was their favourite herb for anxiety?  
• They were also asked how long they had been in practice and to add any additional 
comments should they wish to do so. 
3. Results and discussion 
Of 377 questionnaires sent, 62 practitioners responded (16%).  Of all responders, 57 (92%) 
said they regularly prescribe S. lateriflora.  Length of time in practice and experience varied 
widely but generally the responders comprised a group of highly experienced herbal 
practitioners. The average length of time in practice was 9.03 years (SD = ± 7.14) and the 
average time spent with patients per week was 10 hours per practitioner. 
3.1. Actions and indications attributed to S. lateriflora 
The majority of respondents provided more than one indication and/or action and use of S. 
lateriflora (Table 1).  There was some confusion over the difference between actions and 
indications and most common conditions for which it is prescribed.  For example, 77% (n = 
48) of respondents said they would prescribe it for anxiety but only 35% (n = 22) suggested it 
has an anxiolytic action and only 18% (n = 11) gave anxiety as an indication for the herb.  
For simplicity, ‘indications’ and ‘reasons for prescribing’ have been amalgamated in Table 1. 
The confusion between actions and indications and reasons for prescribing is interesting and 
deserves consideration by herbalists generally; it calls into question how a misunderstanding 
of the language might potentially impose restrictions to the way in which herbs are used. If 
so, such an impediment may impact upon herbal practice as a whole.  Rigorous scientific 
research could explore this issue. 
3.2. The practitioners’ choice for anxiety 
Results indicate the principal use of S. lateriflora is for relief of anxiety, stress or associated 
conditions with most 77% (n = 48) survey respondents stating they would prescribe it 
specifically for anxiety and all said they would prescribe it for anxiety-related co-morbidities.  
7 
 
When asked what is their preferred herb for anxiety, twenty five 25 (40%) chose S. lateriflora 
(Figure 2).  It is interesting to note that one respondent indicated their preferred anxiolytic as 
being S. baicalensis as,  although S. baicalensis root is most commonly used for 
inflammation (Joshee et al. 2002), it is reported to have been used as a sedative (Liao et al. 
1998).  Conversely, S. lateriflora is reported to have been traditionally used for inflammation. 
The Iroquai tribe, for example, used it ‘to keep the throat clear’ (Joshee et al. 2002).  
Additionally, both S. lateriflora and S. baicalensis have been found to inhibit 
cyclooxegenases in vitro (Gafner et al. 2004; Jia et al. 2007).   
 
Common reasons for prescribing S. lateriflora are provided in Table 1.  All respondents who 
regularly prescribe S. lateriflora (92%) identified use for anxiety as distinct from depression 
and whilst some reported it useful also in depression, two respondents reported it as 
unsuitable for significant depression (described as “mentally depressed states” and “severe 
depression”) as in their opinion it tended to exacerbate it.  Usefulness for insomnia and sleep-
related disorders was reported by 33 (53%) respondents.  Practitioners who prescribe for poor 
sleep invariably described it to be related to an overactive mind, obsessive or racing thoughts, 
worry and anxiety.  
 
Table 1:  Actions and indications attributed to S. lateriflora 
 
Actions attributed to S. lateriflora  
(n = 62) 
N Indications/reasons for prescribing S. 
lateriflora (n= 62) 
N 
Nervine/ nerve trophorestorative 40 Anxiety 59 
Anxiolytic 22 Insomnia and other sleep-related disorders 33 
Relaxant 20 Stress 21 
Mildly sedative 14 Migraine and other types of headaches 13 
Calming  8   
Antispasmodic or spasmolytic  8 Depression 9 
Cooling  4 Drug withdrawal and addiction 8 
Tranquilising  4 Nervous and muscular tension 7 
Anti-inflammatory  3 Panic attacks 7 
Anti-stress  2 Fear and phobias  7 




Anti-allergy  2 Physical and mental exhaustion 5 
Parasympathetic  1 Excessive thought processes 5 
Anti-panic 1 Hypertension 5 
An emotional balancer 1 Palpitations 5 
Antidepressant 1 Irritability 3 
Supporting 1 Twitches and spasms of nervous 
origin/convulsions 
2 
Digestive tonic 1 Premenstrual syndrome (PMS) 2 
Sustaining 1 Allergies 2 
Anti busy brain 1 To put things into perspective 2 
Bringing focus 1 Nervousness 2 
  Chronic fatigue syndrome 2 
  Irritable bowel syndrome 2 




Other anxiety-related conditions given by practitioners as reasons for prescribing included 
for: ‘those who sigh a lot’, frustration, menopausal mood swings, despondency, neuralgia, 
nerve weakness, emotional instability, shock, feelings of not coping, tinnitus, debility, hot 
flashes triggered by stress, low mood, grand mal, Attention Deficit Hyperactivity Disorder, 




Key: Avena = A. sativa (oats); Crataegus = Crataegus spp. (hawthorn); Hypericum = H. perforatum (St John’s wort); Lavandula = 
Lavandula spp. (lavender); Leonorus = L. cardiaca (motherwort); Matricaria = M. recutita (German chamomile); Melissa = M. officinalis 
(balm); None = no preference; Passiflora = P. incarnata (passion flower); Piper = Piper methysticum  (kava-kava); S. baicalensis (baical 
skullcap); S. lateriflora (American skullcap); Stachys = S. betonica (wood betony);  Tilia = Tilia spp (linden); Valeriana = Valeriana 
officinalis (valerian); Verbena = Verbena officinalis (vervain).   
 
NB:  Many survey respondents gave more than one choice but overall the herb of choice was S. lateriflora. 
 
Figure 2 Anxiolytic herbs as preferred by survey respondents 
 
3.3. Duration of treatment 
The survey respondents reported the herb as being used over a range of time periods from 
immediate short-term use to several years, with positive response expected to be experienced 
by the patient within the first two weeks and persisting throughout the period of use.  
 
According to 8% (n = 5) of respondents who did not state a timescale this is dependent on the 
health of a patient, the condition presented by a patient and its severity, how long they have 
been ill and patient compliance.  In the words of one practitioner: ‘as long as it takes’.  All 
other respondents gave a lower and/or an upper limit.  Rarely, it may be prescribed as a one-
off but in general the minimum length of time it is prescribed is for 1 or 2 weeks (11%; n = 
6).  At least 30% (n = 17) of user respondents consider prescribing it long-term (6 months or 
more), sometimes for years (9%; n = 5), although some stated ‘long term’ without being 
explicit about the timescale.  Those who stated ‘several months’ were not included as long-
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term prescribers as it is unknown whether this could mean up to 6 months or more than 6 
months.  Of those who set an upper limit on treatment length 31% (n = 18) stated they would 
treat for up to 4 months.  It is difficult to ascertain average treatment length as many replies 
were not explicit.  What is clear, however, is that it ranges from one-offs to several years. 
3.4. Responses looked for in patients 
Sleep quality was a major factor in assessing mental state improvement with 53% (n = 30) of 
S. lateriflora prescribers stating they would expect patients to sleep better; for example by 
sleeping longer, with less waking in the night, an ability to get to sleep and feeling refreshed 
in the morning.  Many (37%; n = 21) felt they would be likely to notice that their patients 
were better able to cope with the stresses daily life.  A reduction in anxiety and feeling calmer 
would be looked for in patients by 33% (n = 19) and 32% (n = 18) of practitioners 
respectively.  In general, respondents expected their patients to feel happier, less depressed or 
tearful, calmer, more relaxed, less irritable, less stressed, tense or nervous and more in control 
of their emotions with elevated mood.  They also expected a concomitant resolution or 
reduction of stress- and anxiety-related physical symptoms such as headaches, digestive 
disturbances, PMS, inflammatory skin conditions, twitches and spasms, and cardiovascular 
problems such as hypertension, tachycardia and palpitations.   
3.5. Benefits reported by patients 
The benefits most often reported by patients to their practitioners were feeling calmer, 
improved sleep patterns and sleep quality, and better able to cope in stressful situations. Other 
positive effects were mood elevation, increased energy, being more focused and feeling 
generally more relaxed. Some user respondents (19%; n = 11) answered that it is difficult to 
determine what patients have reported from using S. lateriflora as they never prescribed it as 
a single herb but always mixed it with others.   
3.6. Effectiveness response time 
When asked: “after what length of time would you expect to see a response?” answers were 
again often implicit rather than explicit.  Most provided a range of timescales e.g. “one to two 
weeks”.  Some practitioners did not provide a minimum or maximum timescale, only ‘one 
month of treatment for every year they have been ill’ or ‘longer term’ and many responded to 
the question with ‘few days or ‘few weeks’.  One said it was difficult to say as they always 
prescribe S. lateriflora in combination with other herbs and therefore values for neither the 
average nor minimum and maximum expected response time could be ascertained. 
 
Most said it was dependent on the condition being treated and many said that improvement 
was time and/or dose dependent - practitioners’ own words but suggesting improvement over 
the minimum response time provided and/or with what they perceive as adequate doses (see 
Figure 3) - but usually noticeable within a few days; and that continuation of treatment for 
periods beyond the first signs of improvement was beneficial to the patient.  Responses by 12 
practitioners suggest, however, that S. lateriflora may show an effect immediately or within 
hours.  Twenty practitioners questioned expect to see some results in one or two weeks.  Of 
total expected minimum response times provided (n = 56), only 11 practitioners did not 
expect S. lateriflora to show an effect before 3 weeks.  The maximum expected response time 




3.7. Dosing strategies (posology) 
The weekly ethanol: water tincture dose of S. lateriflora most commonly prescribed (Figure 
3) by user respondents is 20 ml (33.3 %) followed by 30 ml (19%).  As the average marc: 
menstruum ratio was 1: 3 in 25% ethanolic extract the most commonly prescribed weekly 
dose expressed as crude, dried herb was around 7g and10 g respectively.  The range of doses 
represents approximately 1.7-35 g crude, dried or fresh herb in 1:3 ethanol: water (w/v) per 
week, and the median daily dose is thus 3 ml, which is equivalent to 1 mg at this marc to 
menstruum ratio. Tinctures are the preferred mode of administration by the majority (96%; n 
= 55) of respondents who prescribe the herb.  The main reasons given were that tinctures are 
generally more convenient than dried herb and therefore better for patient adherence.  There 
is also a belief that tinctures are more effective than dried herb.  Tinctures may be made from 
either fresh or dried organic and non-organic herb and many user respondents (63%; n = 36) 
said they prefer to use organic S. lateriflora and 42% (n = 24) prefer tinctures made from the 




Figure 3 Most commonly administered weekly doses of ethanol: water S. lateriflora tincture 
 
All S. lateriflora users responding to the survey prescribe the herb in combination with other 
herbs.  Only 9% (n = 5) regularly prescribed S. lateriflora as a single herb so it is difficult to 
draw conclusions about the perceived actions of S. lateriflora used on its own.  Nevertheless 
the practitioners appeared to be confident in attributing specific anxiolytic and related actions 
and responses to S. lateriflora as distinct from other herbs in a mixture.  Reasons are unclear 
but this perhaps reflects a combination of empirical, anecdotal and scientific knowledge 
relating to each of the herbs prescribed simultaneously. Furthermore, respondents (9% of 
users; n = 5) prescribing it as a single herb reported positive feedback from their patients such 
as reduced anxiety, fewer and less intense panic attacks, feeling of well-being, feeling more 
positive, more able to cope.  Significantly, a relapse of anxiety symptoms in some patients 
11 
 
was noticed by one practitioner prescribing the herb in combination with other (non-
anxiolytic) herbs whenever it was removed from the mixture.  
 
3.8. Contraindications and side-effects 
While the majority of respondents (81%; n = 50) did not consider S. lateriflora to be 
contraindicated for any conditions, the other 19% (n = 12) said they would not prescribe it to 
severely depressed patients, those with bipolar disorder or other specific mental conditions, to 
those with epilepsy, thyroid conditions, in pregnancy or to children.  It may be possible that 
herbalists are unlikely to prescribe any herbs for situations where safety is unknown. 
The herb was reported as being well tolerated and with only minor and infrequent side effects 
(reported by 7 prescribers); including mild digestive upsets, worsening of depression, 
daytime drowsiness, light-headedness and vivid dreaming.  It is uncertain whether any of 
these side effects could definitely be attributed to S. lateriflora.  There were no reports of 
toxicity. 
3.9. Survey response rate 
It is not clear why there was such a low response rate to the survey questionnaire (despite two 
follow-ups, an oral presentation alert at a NIMH conference and an advertisement in a NIMH 
newsletter).  Several reasons for low feedback could be postulated.  One is that medical 
herbalists tend to receive a number of survey response requests during any given year, mainly 
from undergraduates embarking upon their dissertations, and may therefore be suffering from 
‘survey fatigue’.  It could be that some didn’t feel the survey was relevant to their practice if 
they were non-prescribers of S. lateriflora.  This is difficult to assess but if this was the case 
then generalisability across herbal medicine practitioners would have been affected by non-
response bias (Cummings et al. 2001).  Some may have been deterred by the length of the 
questionnaire and the fact that questions were in the main open-ended, requiring considerable 
time and effort on the part of already busy practitioners, many of whom are doing more than 
one job or are studying.  Studies of response rates to surveys have demonstrated that the more 
user-friendly a survey is the more likely it is to have a high response rate (LaGarce & Kuhn 
1995).  A fair amount of typing was required to fully answer the questions so it could not be 
considered to be as user-friendly as a quantitative scaling method, for example. 
3.10. Conclusions 
This study has added to the literature in that it has shown that S. lateriflora is prescribed for a 
range of related conditions and its widespread use for sleep disorders has broadened the 
indications in the British Herbal Pharmacopoeia.  Furthermore, the revelation that herbalists 
ascribe the action of a compound mixture to the herb has provided empirical evidence of its 
efficacy. 
 
It is recognised that the response rate (16%) for this pilot survey was low and respondents 
include only those with access to email.  It may therefore not be representative of all UK and 
Ireland herbal medicine practitioners.  An advantage of email surveys is that they are fast and 
cost-effective and provide geographical diversity but exclusion includes those without access 
to email.  Furthermore, responses may have been mainly from those who have had experience 
of the herb.  Non-responders could possibly be mostly non-prescribers.  Importantly, it is 
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possible that those who do not prescribe S. lateriflora may not do so because they do not find 
the herb useful.  Although this is speculation it could be a confounding factor.  The poor 
response rate and the propensity of respondents to administer S. lateriflora in combination 
with other herbs make it impossible to rely on evidence regarding the efficacy of the herb 
from the pilot practitioner survey alone.  A future survey could include herbal practitioners 
from other professional bodies such as the Council of Practitioners of Phytotherapy.  In 
addition, contact with herbalists internationally may provide a more useful indication of the 
benefits of this herb. Because of the low response rate a future survey could contain fewer 
closed questions and use a world-wide web electronic format so that respondents could have 
the option to simply click multiple choices with a computer mouse.  Furthermore, it would be 
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